臨床外科71巻4号

2016年04月発行

特集 大腸癌肝転移—最新の治療ストラテジー 総論

大腸癌肝転移の現状

著者： 江本成伸¹ 石原聡一郎¹ 渡邉聡明¹

所属機関： ¹東京大学腫瘍外科

ページ範囲：P.388 - P.392

【ポイント】
◆肝臓は大腸癌の転移巣として最も頻度の高い臓器である．
◆肝転移の治療は肝切除，全身化学療法，肝動注療法および熱凝固療法に大別でき，根治切除可能な肝転移には肝切除が推奨される．
◆化学療法の進歩により，切除不能であったものが切除可能にconversionする症例が存在し，長期生存が得られる場合がある．
◆患者の耐術能やPSを考慮して治療方針を決定する必要がある．

参考文献

1）大腸癌研究会（編）：大腸癌治療ガイドライン　医師用2014年版，金原出版，2014

2）大腸癌研究会（編）：大腸癌治療ガイドライン　医師用2010年版，金原出版，2010

3）大腸癌研究会（編）：大腸癌治療ガイドライン　医師用2005年版，金原出版，2005

4）大腸癌研究会（編）：大腸癌取扱い規約第8版，金原出版，2013

5）Yamaguchi M, Yamanori A, Igarashi M, et al：A resected case of liver metastasis from colon cancer that occurred 13 years after a colectomy. Hepatogastroenterology 55：2221-2223, 2008

6）Shinto E, Takahashi K, Yamaguchi T, et al：Validation and Modification of the Japanese Classification System for Liver Metastases from Colorectal Cancer：A Multi-institutional Study. Ann Surg Oncol 22：3888-3895, 2015

7）Abdalla EK, Vauthey JN, Ellis LM, et al：Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239：818-825；discussion 825-817, 2004

8）Kato T, Yasui K, Hirai T, et al：Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy：analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46：S22-31, 2003

9）Lam VW, Spiro C, Laurence JM, et al：A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19：1292-1301, 2012

10）Adam R：Developing strategies for liver metastases from colorectal cancer. Semin Oncol 34：S7-11, 2007

11）Bismuth H, Adam R, Levi F, et al：Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224：509-520；discussion 520-502, 1996

12）Choti MA, Sitzmann JV, Tiburi MF, et al：Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235：759-766, 2002

13）Adam R, Delvart V, Pascal G, et al：Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy：a model to predict long-term survival. Ann Surg 240：644-657；discussion 657-648, 2004

14）Adam R, Wicherts DA, de Haas RJ, et al：Patients with initially unresectable colorectal liver metastases：is there a possibility of cure? J Clin Oncol 27：1829-1835, 2009

15）Ychou M, Hohenberger W, Thezenas S, et al：A randomized phase Ⅲ study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20：1964-1970, 2009

16）Mitry E, Fields AL, Bleiberg H, et al：Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer：a pooled analysis of two randomized trials. J Clin Oncol 26：4906-4911, 2008

17）Portier G, Elias D, Bouche O, et al：Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases：FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24：4976-4982, 2006

18）Kanemitsu Y, Kato T, Shimizu Y, et al：A randomized phase Ⅱ/Ⅲ trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer：Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol 39：406-409, 2009

19）NCCN Clinical Practice Guidelines in Oncology：Colon Cancer Version 2, 2015（2015）

20）NCCN Clinical Practice Guidelines in Oncology：Rectal Cancer Version 2, 2015（2015）

21）Maughan TS, Adams RA, Smith CG, et al：Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer：results of the randomised phase 3 MRC COIN trial. Lancet 377：2103-2114, 2011

22）Primrose J, Falk S, Finch-Jones M, et al：Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis：the New EPOC randomised controlled trial. Lancet Oncol 15：601-611, 2014

23）Venook AP, Niedzwiecki D, Lenz HJ：CALGB/SWOG 80405：Phase Ⅲ trial of irinotecan/5-FU/leucovorin（FOLFIRI）or oxaliplatin/5-FU/leucovorin（mFOLFOX6）with bevacizumab（BV）or cetuximab（CET）for patients（pts）with KRAS wild-type（wt）untreated metastatic adenocarcinoma of the colon or rectum（MCRC）. J Clin Oncol, 2014 ASCO Annual Meeting Abstracts 32, LBA3（2014）

24）Schmoll HJ, Van Cutsem E, Stein A, et al：ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23：2479-2516, 2012

25）Van Cutsem E, Cervantes A, Nordlinger B, et al：Metastatic colorectal cancer：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25（Suppl 3）：iii1-9, 2014